Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Thomas Jefferson University
H. Lee Moffitt Cancer Center and Research Institute
Takeda
Gilead Sciences
Wake Forest University Health Sciences
Columbia University
Allogene Therapeutics
University of Ulm
Pfizer
National Institutes of Health Clinical Center (CC)
Acerta Pharma BV
University of Pittsburgh
CytomX Therapeutics
M.D. Anderson Cancer Center
Columbia University
Merck Sharp & Dohme LLC
Novartis
GlaxoSmithKline
Merck Sharp & Dohme LLC
Virginia Commonwealth University
Regeneron Pharmaceuticals
Amgen
Incyte Corporation
Affimed GmbH
Incyte Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Istari Oncology, Inc.
City of Hope Medical Center
Celgene
Faeth Therapeutics
Aprea Therapeutics
MacroGenics
SecuraBio
Juno Therapeutics, a Subsidiary of Celgene
Celgene
SWOG Cancer Research Network
AstraZeneca
Astellas Pharma Inc
University College, London
BeiGene
BeiGene
BeiGene
Seoul National University Hospital
AstraZeneca
University of California, San Diego
Dana-Farber Cancer Institute
Eisai Inc.
M.D. Anderson Cancer Center
pharmaand GmbH